MoneyWorks4Me

Orchid Pharma informs about revision of credit rating

15 Dec 2023 Evaluate

In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulation’) read with Schedule III of Listing Regulation, Orchid Pharma has informed that CARE Ratings vide its letter dated December 14, 2023 has revised the status of the ratings assigned to the Company, which are attached. The Credit Rating letter received from CARE is attached as Annexure. 

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1851.50
Dr. Reddys Labs. 1140.50
Cipla 1357.95
Lupin 2041.60
Zydus Lifesciences 1098.40
View more..